Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 7/20 | 0.48 |
| ▸ | NOS1 | P29475 | 7/20 | 0.48 |
| ▸ | NOS2 | P35228 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290837 | 0.93 | LMNA (0.41) | NOS3NOS1NOS2KDM4ECPT2 | |
| SCHEMBL221453 | 0.87 | NOS1 (0.41) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL6582950 | 0.86 | NOS3 (0.62) | NOS3NOS1NOS2KDM4EADORA2A | |
| SCHEMBL6583013 | 0.85 | CBX7 (0.41) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL222427 | 0.85 | NOS3 (0.48) | NOS3NOS1NOS2KDM4EADORA2A | |
| SCHEMBL221914 | 0.78 | NOS3 (0.63) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL6583956 | 0.76 | NOS1 (0.48) | NOS3NOS1NOS2 | |
| SCHEMBL250384 | 0.76 | NOS3 (0.60) | NOS3NOS1NOS2KDM4EADORA2A | |
| SCHEMBL221361 | 0.73 | NOS3 (0.62) | NOS3NOS1NOS2KDM4EADORA2A | |
| SCHEMBL218605 | 0.72 | NOS3 (0.59) | NOS3NOS1NOS2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRTRIS PHARMACEUTICAS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20070248590-A1 | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRT1, SIRT5, SIRT2 | NOS3 1835/4885NOS1 728/4885NOS2 1029/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | NOS3 1327/4885NOS1 1659/4885NOS2 1778/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | NOS3 1327/4885NOS1 1659/4885NOS2 1778/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NOS3 349/4885NOS1 357/4885NOS2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.